PMS2 and cancer: For carriers of a path_MLH1, path_MSH2, path_MSH6 or path_PMS2 variant, risks of CRC, gynaecological cancer and upper urinary tract cancer were similar regardless of whether they had a previous or prevalent cancer in other organs at inclusion for follow-up (Supplementary Table S8).